Amgen Fights Income Allocations In $3.6B Tax Court Case
Drugmaker Amgen is challenging a $3.6 billion tax bill in the U.S. Tax Court, accusing the IRS of misattributing profits its Puerto Rican subsidiary earned while manufacturing biopharmaceutical products under intercompany license...To view the full article, register now.
Already a subscriber? Click here to view full article